Millington Financial Advisors LLC Has $1.49 Million Position in Novo Nordisk A/S (NYSE:NVO)

Millington Financial Advisors LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 14,352 shares of the company’s stock after purchasing an additional 194 shares during the quarter. Novo Nordisk A/S makes up approximately 1.2% of Millington Financial Advisors LLC’s investment portfolio, making the stock its 25th biggest position. Millington Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,485,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Weatherly Asset Management L. P. acquired a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $226,000. Linden Thomas Advisory Services LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $214,000. Parkside Financial Bank & Trust raised its stake in Novo Nordisk A/S by 28.9% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,941 shares of the company’s stock worth $201,000 after buying an additional 435 shares during the period. Marks Group Wealth Management Inc raised its stake in Novo Nordisk A/S by 0.5% during the 4th quarter. Marks Group Wealth Management Inc now owns 20,502 shares of the company’s stock worth $2,121,000 after buying an additional 106 shares during the period. Finally, RWA Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 366.8% during the fourth quarter. RWA Wealth Partners LLC now owns 92,806 shares of the company’s stock worth $9,601,000 after acquiring an additional 72,924 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 2.7 %

Shares of NVO traded up $3.36 during mid-day trading on Tuesday, hitting $128.62. 3,701,385 shares of the company’s stock were exchanged, compared to its average volume of 4,856,259. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The company has a market cap of $577.19 billion, a PE ratio of 47.55, a P/E/G ratio of 2.05 and a beta of 0.41. The company has a 50-day simple moving average of $126.66 and a 200 day simple moving average of $111.54.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. On average, research analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were given a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio is 49.17%.

Analysts Set New Price Targets

A number of research firms have recently commented on NVO. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. UBS Group initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.